AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Phase 1

Recruiting

• Conditions: Ocular Hypertension; Open-angle Glaucoma
• Interventions: Drug: AGN-193408 SR; Other: Lumigan; Other: Sham Administration; Other: Lumigan Vehicle

• Registration Number: NCT04499248
• Lead Sponsor: AbbVie

Brief Summary

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2020-07-31
• Study First Submitted QC: 2020-07-31
• Study First Posted: 2020-08-05
• Study Start: 2020-11-16
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-05
• Last Update Posted: 2024-12-09
• Primary Completion: 2028-08
• Study Completion: 2028-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

• Participant is willing to withhold his/her IOP (Intraocular Pressure) treatments according to the study requirements, and in the opinion of the investigator, can do so without significant risk.
• Diagnosis of either OAG [open-angle glaucoma] (ie, [POAG], pseudoexfoliation glaucoma,pigmentary glaucoma) or OHT (ocular hypertension) in both eyes.
• Must be pseudophakic (at least 4 months postcataract surgery prior to treatment administration [Cycle 1 Day 1 Administration visit]) in the study eye (Cohort 3 only).

Read More

Exclusion Criteria

• Known allergy or sensitivity to any study medication or its components, any component of the delivery vehicle, procedure-related materials, or diagnostic agents used during the study (eg, topical anesthetic, dilating drops, fluorescein, povidone-iodine).

• Concurrent or anticipated enrollment in an investigational drug or device study or participation in such a study within 2 months prior to the Baseline visit through the final study visit.

• History of intracameral implant in the study eye (eg, Bimatoprost SR, OTX-TIC, ENV515 Travoprost XR).

• History of laser trabeculoplasty within 6 months prior to screening in the study eye.

• History or evidence of clinically relevant, substantial ocular trauma (eg, a traumatic cataract, traumatic angle recession, etc.) in the study eye.

• History or evidence of complicated cataract/lens surgery, as stated in the protocol.

• Intraocular surgery (including cataract surgery) in the study eye within the 4 months prior to treatment administration.

• Any history of corneal graft, including partial grafts (eg, Descemet's Stripping Endothelial Keratoplasty [DSEK], Descemet's Membrane Endothelial Keratoplasty [DMEK]); or incisional refractive surgery (eg, radial keratotomy), other than astigmatic keratotomy or limbal relaxing incisions in the study eye.

• History of herpetic ocular diseases in either eye (including herpes simplex virus and varicella zoster virus).

• Anticipated need for any incisional or laser ocular surgery in either eye during the study.

• History of anatomically narrow angle resulting in evidence of angle changes or any history or closed angle glaucoma in the study eye.

• History or evidence of a peripheral iridotomy/iridectomy in the inferior iris in the study eye.

• Any history of trabeculectomy or other types of incisional glaucoma surgery, including a glaucoma seton or aqueous bypass stents in either eye, or minimally invasive glaucoma surgery (MIGS) type trabecular meshwork surgeries in the study eye.

• Anticipated use of corticosteroids in either eye except for permitted interventions or systemically during the study, or historical use prior to Baseline within:

  • 3 years: intraocular fluocinolone acetonide
  • 6 months: intraocular corticosteroid(s) other than fluocinolone; any injectable periocular or sub-Tenon's/subconjunctival corticosteroid
  • 2 months: systemic (eg, oral, intramuscular, intravenous) or topical ocular corticosteroids
  • 2 weeks: dermal corticosteroids applied to skin of the eyelid(s), around the eye, or adnexa.

• Anticipated use of other topical ocular medications in either eye except for permitted interventions.

• The anticipated wearing of contact lenses in the study eye (Cohort 1) and both eyes (Cohorts 2 and 3) during the study that deviates from the following (contact lens wear is allowed during the study, but is to be temporarily discontinued before study visits, and before and after an Administration Day according to the following):

  • Use of soft lenses should be discontinued at least 3 days prior to Baseline, and use of rigid gas permeable or hard contact lenses should be discontinued at least 1 week prior to Baseline
  • Use of soft lenses should be discontinued at least 3 days and use of rigid gas permeable or hard contact lenses should be discontinued at least 1 week prior to a scheduled study visit or Administration Day visit
  • Use of contact lenses of any kind should be discontinued for 1 week following any AGN-193408 SR administration

• Central corneal thickness of < 480 or > 620 micrometers in both eyes.

• Visual field loss in the study eye that, in the opinion of the investigator, is functionally significant (eg, split fixation, field defect within the central 10 degrees that is visually significant or likely to cause central visual impairment upon progression) or shows evidence of progressive visual field loss within the year prior to Baseline.

• Evidence of macular edema in either eye during screening or in participant's medical history.

• At Screening, evidence of posterior synechia behind the iris inferiorly in the study eye that in the investigator's opinion may inhibit the ability to safely receive at least 1 AGN-193408 SR implant (Cohort 3 only).

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 1 - Dose B	Lumigan	Single dose of AGN-193408 SR Dose B administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
Cohort 1 -Dose A	AGN-193408 SR	Single dose of AGN-193408 SR Dose A administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
Cohort 1 -Dose A	Lumigan	Single dose of AGN-193408 SR Dose A administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
Cohort 1 - Dose B	AGN-193408 SR	Single dose of AGN-193408 SR Dose B administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
Cohort 2 - Dose A	AGN-193408 SR	AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 2 - Dose A	Lumigan	AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 2 - Dose A	Sham Administration	AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 2 - Dose A	Lumigan Vehicle	AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 2 - Dose B	AGN-193408 SR	AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 2 - Dose B	Lumigan	AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 2 - Dose B	Sham Administration	AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 2 - Dose B	Lumigan Vehicle	AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 3 - Dose A	Lumigan	AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 3 - Dose A	AGN-193408 SR	AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 3 - Dose A	Sham Administration	AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 3 - Dose A	Lumigan Vehicle	AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 3 - Dose B	Lumigan	AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 3 - Dose B	AGN-193408 SR	AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 3 - Dose B	Sham Administration	AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
Cohort 3 - Dose B	Lumigan Vehicle	AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.

Primary Outcome Measures

Name	Time	Method
Change from Baseline in Hour 0 Intraocular Pressure (IOP) in the Study Eye	Baseline to Month 36	IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Number of participants experiencing treatment emergent adverse events	Baseline to Month 36

Secondary Outcome Measures

Name	Time	Method
Time to Rescue Treatment or Re-Treatment in the Study Eye	Baseline to Month 36	Time to rescue treatment or the second treatment is defined as the time between the first treatment and the second treatment in the study eye.

Trial Locations

Locations (39)

National Hospital Organization Saitama Hospital /ID# 266953; 🇯🇵 Wako, Saitama, Japan

Walman Eye Center /ID# 252153; 🇺🇸 Sun City, Arizona, United States

Global Research Management /ID# 241699; 🇺🇸 Glendale, California, United States

United Medical Research Institute /ID# 241701; 🇺🇸 Inglewood, California, United States

Lakeside Vision Center /ID# 241698; 🇺🇸 Irvine, California, United States

The Eye Research Foundation /ID# 234528; 🇺🇸 Newport Beach, California, United States

Sacramento Eye Consultants /ID# 241697; 🇺🇸 Sacramento, California, United States

Premiere Practice Management LLC /ID# 235957; 🇺🇸 Torrance, California, United States

Wolstan & Goldberg Eye Associates /ID# 241700; 🇺🇸 Torrance, California, United States

Connecticut Eye Consultants P.C. /ID# 235862; 🇺🇸 Danbury, Connecticut, United States

Nature Coast Clinical Research - Crystal River /ID# 237781; 🇺🇸 Crystal River, Florida, United States

University of Florida Health Ophthalmology - Jacksonville /ID# 243122; 🇺🇸 Jacksonville, Florida, United States

East Florida Eye Institute /ID# 235762; 🇺🇸 Stuart, Florida, United States

Logan Ophthalmic Research Inc. /ID# 252087; 🇺🇸 Tamarac, Florida, United States

Coastal Research Associates /ID# 234649; 🇺🇸 Roswell, Georgia, United States

Midwest Medical Advisors Inc /ID# 235845; 🇺🇸 Carmel, Indiana, United States

Indiana University - Glick Eye Institute /ID# 235887; 🇺🇸 Indianapolis, Indiana, United States

Ophthalmic Consultants of Boston /ID# 236535; 🇺🇸 Boston, Massachusetts, United States

Fraser Eye Care Center /ID# 267100; 🇺🇸 Fraser, Michigan, United States

Midwest Vision Research Foundation at Pepose Vision Institute /ID# 267094; 🇺🇸 Chesterfield, Missouri, United States

Silverstein Eye Centers /ID# 266767; 🇺🇸 Kansas City, Missouri, United States

Tekwani Vision Center /ID# 235149; 🇺🇸 Saint Louis, Missouri, United States

Rutgers New Jersey Medical School Campus, Doctors Office Center /ID# 234365; 🇺🇸 Newark, New Jersey, United States

Northern New Jersey Eye Institute PA /ID# 241545; 🇺🇸 South Orange, New Jersey, United States

Asheville Eye Associates /ID# 234963; 🇺🇸 Asheville, North Carolina, United States

James D Branch MD /ID# 234560; 🇺🇸 Winston-Salem, North Carolina, United States

Oklahoma Eye Surgeons /ID# 252089; 🇺🇸 Oklahoma City, Oklahoma, United States

Drs Fine Hoffman & Sims LLC /ID# 235919; 🇺🇸 Eugene, Oregon, United States

Scott and Christie and Associates /ID# 252284; 🇺🇸 Cranberry Township, Pennsylvania, United States

Advancing Vision Research /ID# 236683; 🇺🇸 Smyrna, Tennessee, United States

Keystone Research /ID# 266772; 🇺🇸 Austin, Texas, United States

St. George Eye Center /ID# 236200; 🇺🇸 Saint George, Utah, United States

Piedmont Eye Center /ID# 246455; 🇺🇸 Lynchburg, Virginia, United States

Vistar Eye Center /ID# 234811; 🇺🇸 Roanoke, Virginia, United States

Kitasato University Hospital /ID# 238880; 🇯🇵 Sagamihara-shi, Kanagawa, Japan

Shimane University Hospital /ID# 238641; 🇯🇵 Izumo-shi, Shimane, Japan

The University of Tokyo Hospital /ID# 238871; 🇯🇵 Bunkyo-ku, Tokyo, Japan

University of Yamanashi Hospital /ID# 238642; 🇯🇵 Chuo-shi, Yamanashi, Japan

Hayashi eye hospital /ID# 267604; 🇯🇵 Fukuoka, Japan